Published in final edited form as:

Planta Med. 2018 July ; 84(9-10): 638–644. doi:10.1055/a-0577-5322.

Antiangiogenic Activity and Cytotoxicity of Triterpenoids and Homoisoflavonoids from *Massonia pustulata* and *Massonia bifolia*.

Sianne L. Schwikkard^{1,2}, Hannah Whitmore², Timothy W. Corson³, Kamakshi Sishtla³, Moses K. Langat^{2,4}, Mark Carew¹, and Dulcie A. Mulholland^{3,4}

¹School of Life Sciences, Pharmacy and Chemistry, Kingston University, Kingston-upon-Thames, United Kingdom.

²Natural Products Research Group, Department of Chemistry, Faculty of Engineering and Physical Sciences, University of Surrey, Guildford, United Kingdom.

³Eugene and Marilyn Glick Eye Institute, Department of Ophthalmology, Indiana University School of Medicine, Indianapolis, U.S.A.

⁴School of Chemistry and Physics, University of KwaZulu-Natal, Durban, South Africa

Abstract

The Hyacinthaceae family (*sensu* APGII) with approximately 900 species in around 70 genera, plays a significant role in traditional medicine in Africa as well as across Europe and the Middle and Far East. The dichloromethane extract of the bulbs of *Massonia pustulata* (Hyacinthaceae *sensu* APGII) yielded two known homoisoflavonoids, (*R*)-5-hydroxy-3-(4-hydroxybenzyl)-7-methoxy-4-chromanone **1** and 5-hydroxy-3-(4-hydroxybenzyl)-7-methoxy-4-chromone **2** and four spirocyclic nortriterpenoids, eucosterol **3**, 28-hydroxyeucosterol **4** and two previously unreported triterpenoid derivatives, (*17S,23S*)-17 α ,23-epoxy-3 β ,22 β ,29-trihydroxylanost-8-en-27,23-olide **5** and (*17S, 23S*)-17 α ,23-epoxy-28,29-dihydroxylanost-8-en-3-on-27,23-olide **6**. Compounds **1**, **2**, **3**, and **5** were assessed for cytotoxicity against CaCo-2 cells using a neutral red uptake assay. Compounds **1**, **2** and **5** reduced cell viability by 70% at concentrations of 30, 100 and 100 μ M respectively. *Massonia bifolia* yielded three known homoisoflavonoids, (*R*)-(4'-hydroxy)-5-hydroxy-7-methoxy-4-chromanone **1**, (*R*)-(4'-hydroxy)-5,7-dihydroxy-4-chromanone **7** and (*R*)-(3'-hydroxy-4'-methoxy)-5,7-dihydroxy-4-chromanone **9**, two previously unreported homoisoflavonoids, (*E*)-3-benzylidene-(3',4'-dihydroxy)-5-hydroxy-7-methoxy-4-chromanone **8** and (*R*)-(3',4'-dihydroxy)-5-hydroxy-7-methoxy-4-chromanone **10**, and a spirocyclic nortriterpenoid, 15-deoxoeucosterol **11**. Compounds **1**, **1Ac**, **7**, **8**, **9** and **10** were screened for antiangiogenic activity against human retinal microvascular endothelial cells. Some compounds

Correspondence: Professor Dulcie A Mulholland, Natural Products Research Group, Department of Chemistry, University of Surrey, Guildford, GU27XH, United Kingdom, d.mulholland@surrey.ac.uk.

Supporting information

Photographs of plant material (S1), spectra for compounds **5**, **6**, **8** and **10** (S2) and results of on HREC cell proliferation studies (S3) are available as Supporting Information.

Conflict of Interest

The authors declare there is no conflict of interest.

showed dose-dependent antiproliferative activity and blocked endothelial tube formation, suggestive of antiangiogenic activity.

Keywords

Massonia species; Hyacinthaceae; homoisoflavonoids; spirocyclic nortriterpenoids; cytotoxicity; angiogenesis

Introduction

The genus *Massonia* Houttuyn (Hyacinthaceae, subfamily Hyacinthoideae, tribe Massonieae) [1] is found in the dry areas of South Africa and southwestern Namibia [2]. The genus was named after a Scottish student gardener at Kew, Francis Masson, who collected seeds in the Cape in 1772 [3]. The genus is not known to be used by traditional healers in the region [4]. *Massonia pustulata*, first described in 1791 by Nikolaus von Jacquin, flowers in winter and a dry summer dormancy is required [3]. *Massonia bifolia* (syn. *Whiteheadia bifolia*) was originally described by von Jacquin in 1791 as *Eucomis bifolia*, however, the plant was 'rediscovered' as *Melanthium massoniifolium* in 1804 and as *Whiteheadia latifolia* in 1865 [5]. It was soon after renamed as *Whiteheadia bifolia* due to similarities between the collected specimen and that described by Jaquin [6]. It remained the only species in the *Whiteheadia* genus until 2004 when it was transferred to *Massonia* by Manning et al. due to the results of its DNA sequence analysis [6]. This analysis was prompted by the discovery of a second species, *W. etesionamibensis*, which was tentatively placed in the *Whiteheadia* genus. However, DNA analysis indicated that this species fell between the genera *Whiteheadia* and *Massonia*, suggesting it was an evolutionary stepping stone from *Massonia* to *Whiteheadia*. As such, *Massonia* was given a broader scope to include *Whiteheadia* rather than to create a second, new single-species genus for *W. etesionamibensis* [5]. The phytochemistry of the genus *Massonia* has not been investigated previously.

The subfamily Hyacinthoideae (*sensu* APGII) is characterised by the presence of homoisoflavonoids and spirocyclic nortriterpenoids, usually of the lanostane type [7]. Genera from this family are widely used by traditional healers [7] and homoisoflavonoids isolated from this subfamily have shown anti-inflammatory activity [8–10] and activity against colon (HT-29) and breast cancer (MDA-MB-435) [11,12] cells. Spirocyclic nortriterpenoids have shown activity against HeLa cells [13] and HSC-2 oral squamous carcinoma cells [14–16]. Homoisoflavonoids **1** and **2** and spirocyclic nortriterpenoids **3**, **4**, **5** and **6** were isolated from the dichloromethane extract of the bulbs of *Massonia pustulata* and were assessed for anti-proliferative activity against CaCo-2 cells. Homoisoflavonoids **1**, **7**, **8**, **9** and **10** and the spirocyclic nortriterpenoid **11** were isolated from the ethanol extract of the bulbs of *Massonia bifolia*. Compound **1** was acetylated to aid in separation, forming compound **1Ac**. Since some homoisoflavonoids have been shown to have antiangiogenic activity [17–20], the ability of compounds **1**, **1Ac**, **7**, **8**, **9** and **10** to block in vitro angiogenesis of human retinal microvascular endothelial cells (HRECs) was assessed. Structures are provided in Fig. 1.

Results and Discussion

(*R*)-5-Hydroxy-3-(4-hydroxybenzyl)-7-methoxy-4-chromanone **1** and 5-hydroxy-3-(4-hydroxybenzyl)-7-methoxy-4-chromone **2** have been isolated previously from *Lachenalia rubida* Jacq. [21]. This species, like *Massonia pustulata*, is from the subfamily Hyacinthoideae and endemic to the dry areas of South Africa and Namibia. (*R*)-5-Hydroxy-3-(4-hydroxybenzyl)-7-methoxy-4-chromanone **1** has also been isolated from *Ledebouria graminifolia* Bak. (Jessop) [22]. Eucosterol **3** was first isolated from *Eucomis autumnalis* [23] and later from *Eucomis bicolor* [24], (17*S*, 23*S*)-23,17-epoxy-3 β ,28,29-trihydroxy-27-norlanost-8-en-24-one **4** has been isolated previously from *Eucomis zambesiaca* [24], (*R*)-(4'-hydroxy)-5,7-dihydroxy-4-chromanone **7** has been extracted from *Scilla scilloides* [25], *Leopoldia (Muscari) comosa* [26] and several *Ledebouria* species [10] and (*R*)-(3'-hydroxy-4'-methoxy)-5,7-dihydroxy-4-chromanone **9** has been extracted from *Scilla nervosa* [12]. 15-Deoxoeucosterol **11** has been isolated from several plant species including *Scilla scilloides* [27] and *Pseudoproserpio firmifolium* [28].

Compound **5** was isolated as an amorphous white powder. HR-ESIMS indicated a formula of C₃₀H₄₆O₆ with [M⁺+1] at *m/z* = 503.33666 (C₃₀H₄₆O₆+H requires 503.33726). The FTIR spectrum showed absorption peaks at 3391 cm⁻¹ and 1758 cm⁻¹ due to hydroxyl and carbonyl stretches respectively. NMR spectra indicated a lanosterol-type triterpenoid, with a spirocyclic γ -lactone side chain, typical of the subfamily Hyacinthoideae. The spectroscopic data obtained was very similar to that obtained for the co-isolated eucosterol **3**. As with eucosterol, an 8,9-double bond (δ_c 134.7 and 134.6 respectively), a 3 β -hydroxyl group (δ_c 80.7 and δ_H 3.50 dd, *J* = 6.0 Hz and 12.2 Hz, *W*_{1/2} = 20.3 Hz) [24] and an oxymethylene group at C-29 (δ_c 64.3 and δ_H 4.27, δ_H 3.36) were noted. Four tertiary methyl groups were present at δ_H 0.94 (3H-18), δ_H 0.96 (3H-19), δ_H 1.25 (3H-28) and δ_H 2.24 (3H-30), together with two secondary methyl group resonances at δ_H 1.31, (3H-21) and δ_H 1.39, (3H-26). The presence of the C-17 carbon resonance at δ_c 99.4 together with C-23 fully substituted carbon resonance at δ_c 115.5 indicated a spirocyclic ring system as shown in Fig 2. [29]. An oxymethine proton resonance ascribed to H-22 was noted (δ_H 3.99), and the corresponding carbon resonance (δ_c 84.0) showed correlations in the HMBC spectrum with the H-21 (δ_H 1.31) resonance. Further correlations were seen between the H-22 (δ_H 3.99) and C-17 (δ_c 99.4) resonances, the 3H-26 (δ_H 1.39) and C-27 (δ_c 178.8) and C-24 (δ_c 42.0) resonances and the H-24 (δ_H 2.45) and C-27 (δ_c 178.8) and C-23 (δ_c 115.5) resonances. A correlation was seen between the 3H-21 (δ_H 1.31) and H-22 (δ_H 3.99) resonances in the NOESY spectrum, indicating the hydroxyl group at C-22 was β . The compound was identified as the previously unreported (17*S*,23*S*)-17 α ,23-epoxy-3 β ,22 β ,29-trihydroxylanost-8-en-27,23-olide.

Compound **6** was isolated as an amorphous white powder. The FTIR spectrum showed absorption peaks at 3353 cm⁻¹ and 3250 cm⁻¹ indicative of the presence of hydroxyl groups as well as absorption peaks at 1772 cm⁻¹ and 1723 cm⁻¹ indicative of carbonyl groups. The molecular ion was not seen in the LCMS. The NMR data for compound **6** was similar to that obtained for compound **5**, but differed in showing the presence of a keto group at C-3 (δ_c 213.6), an oxymethylene group at C-28 (δ_c 63.4) and the absence of the hydroxyl group at C-22 (δ_c 32.3 instead of δ_c 84.0). Correlations were seen in the HMBC spectrum between

the H-24 α (δ_{H} 2.00) and H-24 β (δ_{H} 2.72) and C-23 (δ_{C} 113.6) resonances, and between 3H-26 (δ_{H} 1.28) and C-25 (δ_{C} 35.8) resonances. Correlations were also noted in the HMBC spectrum between the 3H-30 (δ_{H} 1.05) and C-8 (δ_{C} 133.5) resonances and between the 3-H-19 (δ_{H} 0.98) and C-9 (δ_{C} 135.4) resonances. Various glycoside derivatives of compound **6** have been isolated from *Scilla peruviana* [13] but the aglycone, (17*S*,23*S*)-17 α ,23-epoxy-28,29-dihydroxylanost-8-en-3-on-27,23-olide, has not been reported previously. Key correlations seen in the HMBC spectra of compounds **5** and **6** are shown in Fig. 2.

HR-ESIMS of compound **9** indicated a $[\text{M} + \text{H}]^+$ ion at m/z 317.1020 corresponding to a molecular formula of $\text{C}_{17}\text{H}_{16}\text{O}_5$ for the compound. The ^1H NMR spectrum indicated this compound was a 3-benzyl-4-chromanone type homoisoflavonoid due to characteristic proton peaks and coupling patterns, including the two H-2 proton resonances at δ_{H} 4.30 (dd, $J=11.3, 4.4$ Hz) and δ_{H} 4.14 (dd, $J=11.3, 7.4$ Hz), the H-3 resonance at δ_{H} 2.84 (m) and the two H-9 resonances at δ_{H} 3.08 (dd, $J=14.4, 5.3$ Hz) and δ_{H} 1.62 (dd, $J=14.4, 10.1$ Hz). Also seen in the proton spectrum was a singlet peak at δ_{H} 3.83 integrating to 3H, indicating that a single methoxy group was present.

The C-4 carbonyl carbon resonance was present at δ_{C} 200.1 and a H-bonded OH group proton resonance was seen at δ_{H} 12.10, confirming the placement of a hydroxy group at C-5. Two *meta*-coupled proton resonances were present (δ_{H} 6.05, $J=2.3$ Hz, H-6 and 6.02 $J=2.3$ Hz, H-8). Both resonances showed a correlation with the single methoxy group proton resonance in the NOESY spectrum, so a methoxy group was placed at C-7.

The B ring was 1,3,4-trisubstituted as shown by the typical splitting patterns of H-2' (δ_{H} 6.70, d, $J=2.1$ Hz), H-5' (δ_{H} 6.73, d, $J=8.0$ Hz) and H-6' (δ_{H} 6.57, dd, $J=8.0, 2.1$ Hz) in the ^1H NMR spectrum. Hydroxy groups were placed at the remaining C-3' and C-4' positions. CD analysis confirmed the configuration at C-3 as *R* due to the negative Cotton effect seen at 290 nm [30] and the compound was identified as the previously unreported 3*R*-(3',4'-dihydroxybenzyl)-5-hydroxy-7-methoxy-4-chromanone.

Compound **10** was isolated as a brown oil. HR-ESIMS indicated a protonated molecular ion at m/z 315.0863 indicating a molecular formula of $\text{C}_{17}\text{H}_{14}\text{O}_6$ for the compound. This compound was identified as the *E*-3-benzylidene homoisoflavonoid analogue of compound **9**, *E*-3-(3',4'-dihydroxybenzylidene)-5-hydroxy-7-methoxy-4-chromanone. The two equivalent H-2 resonances occurred at δ_{H} 5.39 ($J=1.8$ Hz) and the H-9 resonance occurred at δ_{H} 7.72 (br s). The *E* configuration of the double bond was confirmed by the characteristic H-9 proton shift. For the *E*-configuration, H-9 occurs in the δ_{H} 7.58–7.79 region while for the *Z*-configuration, the H-9 resonance occurs at about δ_{H} 6.86 [31].

Compounds **1**, **2**, **3** and **5** were assessed for activity against CaCo-2 cells using a neutral red uptake assay [32, 33] (Fig. 3). Healthy cells take up neutral red into lysosomes whereas dead or damaged cells do not. The amount of neutral red recovered from cells at the end of the assay (as determined by absorbance) is related to the number of viable cells after exposure to a test compound. Cell viability was reduced below 70% by compound **1** at 30 μM and for compounds **2** and **5** at 100 μM . Compound **3** had no effect on cell viability. Compound **2** at 100 μM ($p<0.05$) was of similar activity (22% viability) to actinomycin D (10 $\mu\text{g/mL}$ or 7.96

μM, purchased from Sigma-Aldrich cat no: A1410, 98% purity), a known cytotoxic agent, but at 13x concentration (Fig. 3) Overall, the reported activity was moderate for these compounds.

Compounds **1**, **1Ac** and **7–10** were tested for their effect on proliferation of Human Retinal Microvascular Endothelial Cell (HRECs) (Fig. 4). GI₅₀ values for the compounds, the concentration at which the proliferation of cells is reduced by 50% relative to the DMSO control, were calculated and compounds that only reduced cell proliferation at the highest concentration tested (relative to DMSO control) were reported as having a GI₅₀ > 100 μM. Compound **1** was reported to have the most potent GI₅₀ value of 24.8 μM, compounds **7** and **8** were found to have GI₅₀ values of 35.8 μM and 93.2 μM respectively. Compounds **1Ac**, **9** and **10** had negligible effect on cell proliferation.

We then tested these compounds for anti-angiogenic activity in an *in vitro* Matrigel tube formation assay. This assay models the endothelial cells' ability to form vascular structures. HRECs overall tubule formation decreased significantly and in a dose-dependent manner when compared to DMSO (Fig. 5). Compounds **1**, **7** and **8** again proved most potent of the compounds to block vascular tube formation by HRECs.

The majority of (synthetic) antiangiogenic homoisoflavonoids described previously have trisubstituted A-rings [19], thus the finding that compound **1**, disubstituted on this ring, had reasonably potent activity is novel. Taken together with previous SAR studies on synthetic homoisoflavonoids, these findings help identify homoisoflavonoids that could be pursued towards therapies for neovascular eye diseases such as wet age-related macular degeneration.

Materials and Methods

General experimental procedures

Optical rotations were measured at room temperature on a JASCO-P-1020 polarimeter and IR spectra were recorded using a Perkin-Elmer (2000 FTIR) spectrophotometer using KBr windows. ECD spectra were measured on an Applied Photophysics Chirascan CD spectrometer using a 1 mm cell and CH₃CN as the solvent. ¹H, ¹³C and 2D NMR spectra were recorded on a Bruker AVANCE III NMR spectrometer, operating at 500 MHz for ¹H and 125 MHz for ¹³C, using standard experiments from the Bruker pulse programs library. Chemical shifts are reported in ppm (δ) referencing the solvent signal (CDCl₃) as internal standard respect to TMS (0 ppm), and coupling constants (*J*) are measured in Hz. HR-ESIMS was performed on a Bruker MicroToF Mass Spectrometer, using an Agilent 1100 HPLC to introduce samples. Gravity column chromatography was performed using silica gel (Merck Art. 9385) packed 1 or 4 cm diameter columns. TLC was performed on aluminium precoated silica gel plates (Merck 9385) visualised using anisaldehyde spray reagent. Mass spectra of compounds **9** and **10** were recorded on a Thermo Q-Exactive Orbitrap mass spectrometer using direct HESI injection.

Plant material

Massonia pustulata Jacq. and *Massonia bifolia* Jacq. bulbs were obtained from the collection of the Royal Horticultural Society, Wisley Gardens, Wisley, Surrey, UK (W20150204A WSY and W20150850 WSY respectively) on 10/06/2016 and identity confirmed by comparison against voucher specimens at the Wisley Gardens Herbarium (Section 1S, Supporting Information).

Extraction and isolation of compounds from *M. pustulata* and *M. bifolia*

The bulbs of *Massonia pustulata* (672.1 g) were chopped and extracted by shaking successively for 24 hours in dichloromethane (CH₂Cl₂) and then methanol (MeOH) to yield 8.35 g of CH₂Cl₂ extract and 29.67 g of MeOH extract. The dichloromethane extract was fractionated over silica gel starting with EtOAc:CH₂Cl₂ (1:9) and increasing the concentration of EtOAc. 110 fractions of 20 mL each were collected. Further fractionation over Sephadex LH20 (1:1, CH₂Cl₂:MeOH) yielded compounds **1–6** (20 mg, 8.9 mg, 50 mg, 15 mg, 4.6 mg and 28 mg respectively).

Bulbs of *Massonia bifolia* (263.0 g) were chopped and extracted by shaking for 2×24 hours in ethanol (EtOH) yielding a combined 5.13 g of extract. The extract was fractionated over silica gel, starting with CH₂Cl₂ as solvent and gradually increasing the polarity by addition of use of EtOAc. 95 fractions of 20 mL each were collected. Further fractionation over Sephadex LH20 (1:1, CH₂Cl₂:MeOH) yielded compounds **1** and **7–11** (19 mg, 9.8 mg, 2.3 mg, 3.2 mg, 1.4 mg and 6.9 mg respectively). Structures of compounds **1–11** are shown in Fig. 1.

(1*S*,23*S*)-17*α*,23-epoxy-3*β*,22*β*,29-trihydroxylanost-8-en-27,23-olide (**5**): Amorphous white solid (4.6 mg, 75% pure; from NMR); [α]_D^{23.6} +44.4, (CHCl₃, *c* = 2.7 mg/mL); IR $\nu_{\max}$ cm⁻¹: 3391, 2934, 1758, 1455, 1375, 1034, 736; ¹H- and ¹³C-NMR (500 MHz, CDCl₃) see Table 1 and S2 (Supporting Information). HR-ESI-MS: *m/z* 503.33667 for [M⁺+H]⁺ (calcd. for C₃₀H₄₇O₆, 503.33726)

(1*S*, 23*S*)-17*α*,23-epoxy-28,29-dihydroxylanost-8-en-3-on-27,23-olide (**6**):

Amorphous white solid (28 mg, 70% pure from NMR); [α]_D^{23.6} +3.08 (CHCl₃, *C* = 20.3 mg/mL); IR $\nu_{\max}$ cm⁻¹: 3353, 3250, 2937, 1772, 1723, 1456, 1371, 1046, 736; ¹H- and ¹³C-NMR (500 MHz, CDCl₃) see Table 1 and S2 (Supporting Information). HR-ESI-MS: M⁺ not detected.

3*R*-(3',4'-dihydroxybenzyl)-5-hydroxy-7-methoxy-4-chromanone (**9**): cream/brown oil (3.2 mg); [α]_D^{20.2} = +67.5 (MeOH, *C* = 1.6 mg/mL); CD (CH₃CN) 256 nm (ϵ + 0.25), 286 nm (ϵ - 9.19), 313 nm (ϵ + 1.05); IR $\nu_{\max}$ cm⁻¹: 3349, 2949, 2925, 2848, 1639, 1449, 1014; ¹H- and ¹³C-NMR (500 MHz, MeOD) see Table 2 and S2 (Supporting Information). HESIMS *m/z* 317.1020 [M + H]⁺, (calcd. for C₁₇H₁₇O₆, 317.1025).

E-3-(3',4'-dihydroxybenzylidene)-5-hydroxy-7-methoxy-4-chromanone (**10**): brown oil (1.4 mg); IR $\nu_{\max}$ cm⁻¹: Insufficient quantity of compound; ¹H- and ¹³C-NMR (500 MHz,

MeOD). See Table 2 and S2 (Supporting Information). HESIMS m/z 315.0863 $[M + H]^+$, (calcd. for $C_{17}H_{15}O_6$, 315.0868)

Pharmacological Assays

Neutral red assay

CaCo-2 human colon carcinoma cells (CACO-2 (ECACC 86010202)) from Public Health England, UK, were cultured in EMEM (Eagle's Minimum Essential Medium, ATCC/LGC Standards) supplemented with 10% FBS, 2 mM glutamine, 1% non-essential amino acids, 100 U/mL penicillin/100 U/mL streptomycin, and maintained in 5% CO₂/95% air in an incubator at 37°C. Cells were plated in 96 well plates at 2×10^4 cells/well for 48 hours. Cells were then treated for 48 hours with one of the following, in 4 replicates: culture medium alone (untreated control); 0.1% DMSO (vehicle control; maximum DMSO exposed to cells); actinomycin D 10 µg/mL (positive control); test substances at 1, 3, 10, 30 and 100 µM (diluted from a 100 mM stock in DMSO). Cells were washed with PBS, and neutral red (25 µg/mL in culture medium, diluted from a stock of 2.5 mg/mL in ultrapure water) was added for 3 hours, cells were washed with PBS, and neutral red extracted in 50% ethanol/water with 1% acetic acid. Absorbance was read at 540 nm. Data are reported from 5 independent experiments (different cell passages). The mean absorbance of wells without cells (blank) was subtracted from all other readings. Plates were accepted for analysis given adequate neutral red loading in vehicle treated cells (>0.18 absorbance units) and positive control activity (<60% viability); Z factor values were in the range 0.68 to 0.88. Replicates were averaged to give one treatment value per plate. All plate treatment values were divided by the *mean* value of vehicle-treated cells on the same plate, so data was normalised as percentage of maximum cell viability. The plate treatment values were averaged to produce group means of $n=5$. Analysis of multiple means was performed by one way ANOVA with Dunnett's multiple comparison test against the untreated cells (negative control) value, using GraphPad Prism 6.

HREC proliferation assay

Endothelial Growth Medium (EGM-2) was prepared by mixing the contents of an EGM-2 "Bullet Kit" (Cat. no. CC-4176) with Endothelial Basal Medium (EBM) (Lonza). The EGM-2 "Bullet Kit" contains hydrocortisone, human fibroblast growth factor (hFGF), VEGF, R3-insulin like growth factor (R3-IGF-1), ascorbic acid, human epidermal growth factor (hEGF), gentamycin and heparin along with 2% foetal bovine serum (FBS). Human Retinal Endothelial Cells (HRECs) and proprietary Attachment Factor were purchased from Cell Systems (Kirkland, WA, USA). HRECs were used for cell proliferation studies between passages 5 and 7.

The base of a tissue culture flask (10 cm²) was washed with 1 mL of attachment factors and aspirated. Cryopreserved cells were removed from liquid nitrogen storage and defrosted just prior to use. Cells were transferred into EGM-2 media (5 mL) which was then centrifuged (2 mins, 270xg). The liquid above the cell pellet was aspirated off and the cell pellet was resuspended in 10mL EGM-2 and transferred into the flask. The tube was then incubated overnight (37°C, 5% CO₂) until cells reached confluence. Medium was aspirated and the

cells washed with PBS (3 mL). PBS was aspirated and 500 μ L TrypLE (Life Technologies) added and coated over the surface of the cells for a maximum of 30 seconds. Trypsin was then aspirated and EGM-2 medium (2 mL) was added to the tube to wash cells from the surface. The resulting cell slurry was transferred to a Falcon tube (15 mL) and diluted with sufficient EGM-2 to seed approximately 2,500 cells per well.

The required 2,500 cells/well in 100 μ L medium were incubated in the centre 48 wells of a 96-well clear bottom black plates for 24 hours, with the surrounding 48 wells containing 100 μ L deionized, sterilised water. Standard 1:10 dilutions of compounds in DMSO ranged from 100 mM to 100 nM such that seven concentrations of each compound were tested and the eighth and final well for testing containing DMSO as a control. Cells were treated with 1 μ L of different concentrations of each test compound and control, resulting in a final in-well concentration range of 1 nM to 1 mM with a final DMSO concentration of 1% in all wells. All compounds were tested in triplicate, and our previously-reported synthetic, antiangiogenic homoisoflavonoid SH-11037 [19] was included as a positive control. Treated cells were incubated for a further 48 hour period.

At the end of this incubation period, AlamarBlue reagent (11.1 μ L) was added and after 4 hours of incubation, fluorescence readings were taken with excitation and emission wavelengths of 560 nm and 590 nm respectively. Data were analyzed and dose response curves generated using GraphPad Prism software (v. 6.0) (S3, Supporting Information).

***In vitro* Angiogenesis Assay**

A Matrigel based tube formation assay was performed as previously described [34]. Briefly, 50 μ L Matrigel was allowed to solidify in a 96 well black, clear bottom plate at 37°C for 20 minutes. HRECs were added to the solid Matrigel at 15,000 cells/well in 100 μ L EGM-2 and dosed with appropriate concentrations of compound with 1 μ L DMSO/well. Tube formation was observed every 2 hours by brightfield microscopy and images were taken after 8 hours of tube formation. Six images per treatment were analyzed with AngiogenesisAnalyzer plugin for ImageJ [35], and HREC total tubule length for treated cells was normalized to DMSO. Statistical analysis was completed using GraphPad Prism.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgements

S Schwikkard would like to thank the Daphne Jackson Trust, the Royal Society of Chemistry and the University of Surrey for supporting this work. H Whitmore acknowledges a University of Surrey PhD Scholarship. We thank P Cumbleton, C Wells and C Smith and Wisley Gardens for providing plant material for this investigation. We thank Dr C Costa for providing mass spectra using the DAPNE-IBA instrument funded under the EPSRC EP/P001440/1 grant. TW Corson was supported by NIH/NEI R01EY025641 and an unrestricted grant from Research to Prevent Blindness, Inc.

References

1. Martínez-Azorin M, Pinter M, Crespo MB, Slade J, Deutsch G, and Wetschnig W. Clarification of *Massonia echinata* and some other frequently misunderstood *Massonia* species (Asparagaceae, Scilloideae), with the description of *M. pseudoechinata* and *M. roggeveldensis*. *Phytotaxa* 2015; 239: 101–129
2. Martínez-Azorin M, Pinter M, Crespo M, Pfosser M, and Wetschnig W. *Massonia mimetica* (Hyacinthaceae, Hyacinthoideae), a new remarkable species from South Africa. *STAPFIA* 2013; 99: 187–197
3. Jacquin NJ. *Plantarum rariorum horti caesarei Schoenbrunnensis descriptiones et icones*. Schoenbrunn (Austria), 1804.
4. DeBeer J. An Ethnobotanical survey of the Agter-Hantam region, Northern Cape Province of South Africa. University of Johannesburg, 2012.
5. Manning JP, Goldblatt P, Saunders R. 721. *Massonia bifolia*: Curtis's Botanical Magazine 2011; 28: 324–332
6. Manning JC, Goldblatt P, and Fay M. Revised generic synopsis of Hyacinthaceae in sub-Saharan Africa, based on molecular evidence, including new combinations and the new tribe Pseudoprosperaeae. *Edinb J Bot* 2003; 60: 533–568
7. Mulholland DA, Schwikkard SL, Crouch NR. The chemistry and biological activity of the Hyacinthaceae. *Nat Prod Reports* 2013; 30: 1165–1210
8. Gaidamashvili A, van Staden J. Prostaglandin inhibitory activity by lectin-like proteins from South African medicinal plants. *S Afr J Bot* 2006; 72: 661–663
9. du Toit K, Kweyama A, Bodenstein J. Anti-inflammatory and antimicrobial profiles of *Scilla nervosa* (Burch.) Jessop (Hyacinthaceae): *S A J Sci* 2011; 107: 96–100
10. Waller CP, Thumser AE, Langat MK, Crouch NR, Mulholland DA. COX-2 inhibitory activity of homoisoflavanones and xanthenes from the bulbs of the Southern African *Ledebouria socialis* and *Ledebouria ovatifolia* (Hyacinthaceae: Hyacinthoideae) *Phytochemistry* 2013; 95: 284–290 [PubMed: 23859260]
11. Abegaz BM. Novel phenylanthraquinones, isofuranonaphthoquinones, homoisoflavonoids, and biflavonoids from African plants in the genera *Bulbine*, *Scilla*, *Ledebouria*, and *Rhus*. *Phytochem Rev* 2002; 1: 299–310
12. Silayo A, Ngadjui BT, Abegaz BM. Homoisoflavonoids and stilbenes from the bulbs of *Scilla nervosa* subsp *rigidifolia*. *Phytochemistry* 1999; 52: 947–955
13. Mimaki Y, Nishino H, Ori K, Kuroda M, Matsui T, Sashida Y. Lanosterol oligosaccharides from plants of the subfamily Scilloideae and their antitumor-promoter activity. *Chem Pharm Bull* 1994; 42: 327–33. [PubMed: 8149459]
14. Ori K, Koroda M, Mimaki Y, Sakagami H, Sashida Y. Lanosterol and tetranorlanosterol glycosides from the bulbs of *Muscari paradoxum*. *Phytochemistry* 2003; 64: 1351–1359 [PubMed: 14629999]
15. Ori K, Kuroda M, Mimaki Y, Sakagami H, Sashida Y, Norlanostane and lanostane glycosides from the bulbs of *Chionodoxa luciliae* and their cytotoxic activity. *Chem Pharm Bull* 2003; 51: 92–95 [PubMed: 12520136]
16. Kuroda M, Mimaki Y, Ori K, Koshino H, Nukada T, Sakagami H, Sashida Y. Lucilianosides A and B, two novel tetranor-lanostane hexaglycosides from the bulbs of *Chionodoxa luciliae*. *Tetrahedron* 2002; 58: 6735–6740
17. Shim JS, Kim JH, Lee J, Kim SN, Kwon HJ. Anti-angiogenic activity of a homoisoflavanone from *Cremastra appendiculata*. *Planta Med* 2004; 70: 171–173 [PubMed: 14994197]
18. Basavarajappa HD, Lee B, Fei X, Lim D, Callaghan B, Mund JA, Case J, Rajashekhar G, Seo SY, Corson TW. Synthesis and mechanistic studies of a novel homoisoflavanone inhibitor of endothelial cell growth. *PLoS One* 2014; 9: e95694 [PubMed: 24752613]
19. Basavarajappa HD, Lee B, Lee H, Sulaiman RS, An H, Magana C, Shadmand M, Vayl A, Rajashekhar G, Kim EY, Suh YG, Lee K, Seo SY, Corson TW. Synthesis and biological evaluation of novel homoisoflavonoids for retinal neovascularization. *J Med Chem* 2015; 58: 5015–5027 [PubMed: 26035340]

20. Sulaiman RS, Basavarajappa HD, Corson TW. Natural product inhibitors of ocular angiogenesis. *Exp Eye Res* 2014; 129: 161–171 [PubMed: 25304218]
21. Langlois A, Mulholland DA, Duncan GD, Crouch NR, Edwards TJ. A novel 3-benzylchromone from the South African *Lachenalia rubida* (Hyacinthaceae). *Biochem Syst Ecol* 2005; 33: 961–966
22. Mutanyatta J, Matapa BG, Shushu DD, Abegaza BM, Homoisoflavonoids and xanthenes from the tubers of wild and in vitro regenerated *Ledebouria graminifolia* and cytotoxic activities of some of the homoisoflavonoids. *Phytochemistry* 2003; 62: 797–804 [PubMed: 12620333]
23. Ziegler R, Tamm C. Isolation and structure of eucosterol and 16 β -hydroxyeucosterol, two novel spirocyclic nortriterpenes, and of a new 24-nor-5 α -chola-8,16-dien-oic acid, from bulbs of several *Eucomis* species. *Helv Chim Acta* 1976; 59: 1997–2011 [PubMed: 1017953]
24. Sihra JK, Thumser AE, Langat MK, Crouch NR, Mulholland DA, Constituents of Bulbs of three Species of the Hyacinthaceae (Hyacinthoideae): *Eucomis vandermerwei*, *E. zambesiaca* and *Resnova humifusa*: *Nat Prod Comm* 2015; 10: 1207–1209
25. Ren F, Wang L, Wang F, Li B. Chemical constituents from *Scilla scilloides*: Chinese Trad Herbal Drugs 2014; 14: 1984–1988
26. Adinolfi M, Barone G, Belardini M, Lanzetta R, Laonigro G, Parrilli M. Three 3-Benzyl-4-chromanones from *Muscari comosum*. *Phytochemistry* 1984; 23: 2091–2093
27. Nishida Y, Eto M, Miyashita H, Ikeda T, Yamaguchi K, Yoshimitsu H, Nohara T, Ono M. A new homostilbene and two new homoisoflavonoids from the bulbs of *Scilla scilloides*: *Chem Pharm Bull* 2008; 56: 1022–1025 [PubMed: 18591825]
28. Koorbanally C, Sewjee S, Mulholland D, Crouch N, Dold A. Homoisoflavanones from *Pseudoprospero firmifolium* of the monotypic tribe Pseudoprosperaceae (Hyacinthaceae: Hyacinthoideae): *Phytochemistry* 2007; 68: 2753–2756 [PubMed: 17884116]
29. Ren FC, Wang LX, Yu Q, Jiang XJ, Wang F. Lanostane-Type Triterpenoids from *Scilla scilloides* and Structure Revision of Drimiopsin D: *Nat Prod Bioprospect* 2015; 5: 263–270 [PubMed: 26458926]
30. Moodley N, Crouch N, Mulholland D, Slade D, Ferreira D. 3-Benzyl-4-chromanones (homoisoflavanones) from bulbs of the ethnomedicinal geophyte *Ledebouria revoluta* (Hyacinthaceae). *S Afr J Bot* 2006; 72: 517–520
31. Koorbanally C, Crouch N, Langlois A, DuToit K, Mulholland D, Drewes S. Homoisoflavanones and spirocyclic nortriterpenoids from three *Eucomis* species: *E. comosa*, *E. schijffii* and *E. pallidiflora* subsp. *pole-evansii* (Hyacinthaceae). *S Afr J Bot* 2006; 72: 428–433
32. Repetto G, del Peso A, Zurita JL. Neutral red uptake assay for the estimation of cell viability/ cytotoxicity. *Nat Protoc* 2008; 3: 1125–1131. [PubMed: 18600217]
33. Zhang JH, Chung TDY, Oldenburg KR. A simple statistical parameter for use in evaluation and validation of high throughput screening assays. *J Biomol Screen* 1999; 4: 67–73. [PubMed: 10838414]
34. Basavarajappa HD, Sulaiman RS, Qi X, Shetty T, Sheik Pran Babu S, Sishtla KL, Lee B, Quigley J, Alkhairy S, Briggs CM, Gupta K, Tang B, Shadmand M, Grant MB, Boulton ME, Seo SY, Corson TW. Ferrochelatase is a therapeutic target for ocular neovascularization. *EMBO Mol Med* 2017; 9: 786–801. doi:10.15252/emmm.201606561 [PubMed: 28377496]
35. Carpentier G. Angiogenesis Analyzer for ImageJ (2012) available online: <http://imagej.nih.gov/ij/macros/toolsets/Angiogenesis%20Analyzer.txt>

Fig. 1.
Structures of compounds **1 – 11**

Fig. 2.
Key correlations seen in the HMBC spectra for compounds **5** and **6**.

Fig 3.

Effect of test compounds on Caco-2 proliferation after 48 hours as measured by neutral red uptake. Mean values are shown with SEM. N=5 independent experiments. Effect of positive control (Actinomycin D) was 23% $\pm$ 8% (not shown). * $p < 0.05$ compared to DMSO control.

Fig. 4. Effect of compounds on HREC cell proliferation, normalised to DMSO control. Mean values are shown with SEM, n=3 wells, representative data from at least triplicate experiments. Synthetic homoisoflavonoid SH-11037 was positive control.

Fig. 5.

Tube formation ability of HRECs treated with compounds at 3 concentrations (10 μM, 30 μM, and 100 μM) was observed in Matrigel over 8 hours and images were taken using brightfield microscopy. Tubule length was determined using ImageJ. Synthetic homoisoflavonoid SH-11037 was positive control. *, $p < 0.05$; **, $p < 0.01$; ***, $p < 0.001$ compared to DMSO, ANOVA with Dunnett's *post hoc* tests. Mean values are shown with SEM, $n=6$, representative data from at least triplicate experiments. Images above are tubes formed by HRECs in the presence of 30 μM of each compound above, or 100 nM SH-11037 positive control, or DMSO control. Scale bars = 500 μm.

Table 1¹H and ¹³C NMR data for Compounds **5** and **6** (CDCl₃).

Compound 5			Compound 6	
No.	δC	δH (J in Hz)	δC	δH (J in Hz)
1	35.3	1.21 m, 1.80 m	34.8	1.25 m, 1.79 m
2	28.3	1.30 m	35.8	1.75, 1.25
3	80.7	3.50 dd (6.0, 12.2)	213.6	
4	43.5		48.3	
5	51.2	1.20 m	45.3	1.80 m
6	18.6	1.50 m, 1.80 m	19.5	1.5 m, 1.8 m
7	26.4	1.90 m	26.3	2.05 m
8	134.7		133.5	
9	134.6		135.4	
10	37.4		36.9	
11	20.6	1.99 m, 2.13 m	20.5	1.94, 2.05
12	24.9	2.23 m, 1.55 m	24.7	1.5, 2.0 m
13	49.6		46.7	
14	50.6		50.6	
15	32.0	α 1.35 m β 1.75 m	31.3	α 1.38 m β 1.68 m
16	37.7	α 1.85 dd (5.6, 13.4) β 2.80 dd (9.1, 13.4)	36.9	α 1.80 m β 2.50 m
17	99.4		98.3	
18	19.6	0.94 s	18.6	0.90 s
19	19.8	0.96 s	19.5	0.98 s
20	50.3	2.30 m	43.7	2.25 m
21	15.5	1.31 d (6.8)	18.6	1.05 d (6.8)
22	84.0	3.99 bs (W _{1/2} = 5.4)	32.3	α 1.80 m β 2.55 m
23	115.5		113.6	
24	42.0	α 2.45 dd (4.5, 7.8), β 2.10 dd (7.8, 8.0)	45.2	α 2.00 m, β 2.72 m
25	35.5	2.70 m	35.8	2.97 m
26	16.5	1.39 d (7.4)	15.1	1.28 d (7.0)
27	178.8		179.6	
28	22.2	1.25 s	63.4	α 4.10 d (12.5) β 3.80 d (12.5)
29	64.3	α 3.36 d (11.2) β 4.27 d (11.2)	70.7	α 3.70 d (14.0) β 4.40 d (14.0)
30	26.0	2.24 s	24.7	1.05 s

Table 2¹H and ¹³C NMR data for Compounds **9** and **10** (CD₃OD).

	Compound 9		Compound 10	
No.	¹³ C	¹ H (J in Hz)	¹³ C	¹ H (J in Hz)
2	70.4	α 4.14 (dd, 11.3, 7.4) β 4.30 (dd, 11.3, 4.4)	68.9	5.39 (d, 1.79)
3	48.3	2.84 m	127.4	
4	200.1		187.2	
4a	103.8		105.0	
5	165.2		169.6	
6	95.9	6.05 (d, 2.3)	95.7	6.08 (d, 2.3)
7	169.6		169.5	
8	94.7	6.02 (d, 2.3)	94.7	6.02 (d, 2.3)
8a	164.8		163.9	
9	33.3	α 3.08 (dd, 14.4, 5.3) β 2.62 (dd, 14.4, 10.1)	139.8	7.72 s
1'	131.1		127.0	
2'	117.3	6.70 (d, 2.1)	118.5	6.86 (d, 2.1)
3'	146.7		150.3	
4'	145.2		163.8	
5'	116.6	6.73 (d, 8.0)	116.9	6.87 (d, 8.1)
6'	121.6	6.57 (dd, 8.0, 2.1)	125.1	6.81 (dd, 8.2, 2.1)
5-OH (in CDCl ₃)		12.10 s		
7-OCH ₃	56.4	3.83 s	56.1	3.84 s